This technology is a variant of the synaptic chaperon protein Hspa8, which potentiates neurotransmission to suppress spinal muscular atrophy (SMA) phenotypes in SMA model mice, with further applications in other neurogenerative diseases.
Current therapies for spinal muscular atrophy (SMA) include gene replacement and antisense oligonucleotide technologies. These techniques can improve motor function and extend patient lives, but the patient outcomes are highly variable, and some patients miss the window of opportunity for maximum therapeutic effectiveness.
This technology is a variant of the synaptic chaperone protein Hspa8 (Hsc70), specifically the G470R missense variant, that potentiates neurotransmission through enhanced synaptic SNARE interactions. In spinal muscular atrophy (SMA) model mice, this variant suppresses SMA phenotypes and extends lifespan in SMA model mice. The protein variant may be useful in gene therapy approaches for treating SMA as well as Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases.
This technology has been validated in vivo in SMA model mice.
Patent Pending (US20250241968)
IR CU23056
Licensing Contact: Kristin Neuman